# EDGAR Filing Document

**Accession Number:** 0001809616
**File Stem:** 0001213900-25-084040
**Filing Date:** 2025-9
**Character Count:** 14494
**Document Hash:** a78adaf8220491dbd2c8b4d7fc950c4b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-084040.hdr.sgml**: 20250903

**ACCESSION NUMBER**: 0001213900-25-084040

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20250903

**FILED AS OF DATE**: 20250903

**DATE AS OF CHANGE**: 20250903

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Universe Pharmaceuticals INC
- **CENTRAL INDEX KEY:** 0001809616
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** F4
- **FISCAL YEAR END:** 0930

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40231
- **FILM NUMBER:** 251289822

**BUSINESS ADDRESS:**
- **STREET 1:** 265 JINGJIU AVENUE
- **STREET 2:** JINGGANGSHAN ECON. AND TECH. DEV. ZONE
- **CITY:** JI'AN, JIANGXI
- **STATE:** F4
- **ZIP:** 343100
- **BUSINESS PHONE:** 86-0796-8403309

**MAIL ADDRESS:**
- **STREET 1:** 265 JINGJIU AVENUE
- **STREET 2:** JINGGANGSHAN ECON. AND TECH. DEV. ZONE
- **CITY:** JI'AN, JIANGXI
- **STATE:** F4
- **ZIP:** 343100

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER** 

**PURSUANT TO RULE 13a-16 OR 15d-16** 

**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of September 2025**

**Commission file number: 001-40231**

**Universe Pharmaceuticals INC**

**265 Jingjiu Avenue**

**Jinggangshan Economic and Technological Development Zone**

**Ji'an, Jiangxi, China 343100**

**+86-0796-8403309**

**(Address of principal executive offices)**

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

**Result of the 2025 Annual General Meeting of Shareholders**

On September 2, 2025, Universe Pharmaceuticals INC (the "Company") re-convened its annual general meeting of shareholders, originally convened on August 26, 2025 (the "2025 Annual General Meeting") at 10:00 a.m., Beijing Time, at 265 Jingjiu Avenue, Jinggangshan Economy and Technology Development Zone, Ji'an City, Jiangxi 343100, the People's Republic of China.

At the 2025 Annual General Meeting, the shareholders of the Company adopted resolutions approving all of the proposals considered at the Meeting. A total of 2.55% of the 563,338 votes exercisable as of July 18, 2025, the record date, were present in person or by proxy at the 2025 Annual General Meeting, representing less than one-third (1/3) of the shares carrying the right to vote at the 2025 Annual General Meeting. However, since the 2025 Annual General Meeting was adjourned from August 26, 2025 at 10:00 a.m. Beijing Time due to a lack of quorum, and shareholders representing less than one-third (1/3) of the shares carrying the right to vote were present in person or by proxy at the 2025 Annual General Meeting within fifteen minutes of the time appointed for the 2025 Annual General Meeting, the shareholders present or by proxy shall constitute a quorum in accordance with article 11.2 of the Amended and Restated Articles of Association of the Company currently in effect. A quorum for the transaction of business was therefore present at the 2025 Annual General Meeting.

The results of the votes were as follows:

&nbsp;&nbsp;&nbsp;&nbsp;1. "It is resolved as an ordinary resolution that Gang Lai be re-elected as a director of the Company
to hold office in accordance with the articles of association of the Company until the next annual general meeting of the Company."
("Proposal One")

---

| | | | |
|:---|:---|:---|:---|
| **Resolution** | **For** | **Against** | **Abstain** |
| Proposal One | 11391 | 698 | 2263 |
| Percentage of Voted Shares: | 94.23% | 5.77% |  |

---

&nbsp;&nbsp;&nbsp;&nbsp;2. "It is resolved as an ordinary resolution that Lin Yang be re-elected as a director of the Company to hold office in accordance
with the articles of association of the Company until the next annual general meeting of the Company." ("Proposal Two")

---

| | | | |
|:---|:---|:---|:---|
| **Resolution** | **For** | **Against** | **Abstain** |
| Proposal Two | 11389 | 699 | 2263 |
| Percentage of Voted Shares: | 94.22% | 5.78% |  |

---

&nbsp;&nbsp;&nbsp;&nbsp;3. "It is resolved as an ordinary resolution that Jiawen Pang be re-elected as a director of the Company to hold office in accordance
with the articles of association of the Company until the next annual general meeting of the Company." ("Proposal Three")

---

| | | | |
|:---|:---|:---|:---|
| **Resolution** | **For** | **Against** | **Abstain** |
| Proposal Three | 10835 | 1255 | 2262 |
| Percentage of Voted Shares: | 89.62% | 10.38% |  |

---

&nbsp;&nbsp;&nbsp;&nbsp;4. "It is resolved as an ordinary resolution that Ding Zheng be re-elected as a director of the Company to hold office in accordance
with the articles of association of the Company until the next annual general meeting of the Company." ("Proposal Four")

---

| | | | |
|:---|:---|:---|:---|
| **Resolution** | **For** | **Against** | **Abstain** |
| Proposal Four | 10865 | 1219 | 2268 |
| Percentage of Voted Shares: | 89.91% | 10.09% |  |

---

&nbsp;&nbsp;&nbsp;&nbsp;5. "It is resolved as an ordinary resolution that Yongping Yu be re-elected as a director of the Company to hold office in accordance
with the articles of association of the Company until the next annual general meeting of the Company." ("Proposal Five")

---

| | | | |
|:---|:---|:---|:---|
| **Resolution** | **For** | **Against** | **Abstain** |
| Proposal Five | 10833 | 1251 | 2268 |
| Percentage of Voted Shares: | 89.65% | 10.35% |  |

---

&nbsp;&nbsp;&nbsp;&nbsp;6. "It
is resolved as a special resolution that, subject to and conditional upon, amongst other things: (i) approval from the Grant Court of
the Cayman Islands (the "Court") of the Capital Reduction (as defined below); (ii) registration by the Registrar of Companies
of the Cayman Islands of the order of the Court confirming the Capital Reduction and the minute approved by the Court containing the
particulars required under the Companies Act (Revised) (the "Act") in respect of the Capital Reduction and compliance with
any conditions the Court may impose; (iii) compliance with the relevant procedures and requirements under the applicable laws of the
Cayman Islands to effect the Capital Reduction; and (iv) obtaining of all necessary approvals from the regulatory authorities or otherwise
as may be required in respect of the Capital Reduction, with effect from the date on which these conditions are fulfilled:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) the
par value of each issued Ordinary Share of par value US$11.25 each in the share capital of the Company be reduced to par value US$0.00001
each (the "Capital Reduction") by cancelling the paid-up capital to the extent of US$11.24999 on each of the then issued
Ordinary Shares of par value US$11.25 each;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) the
credit arising from the Capital Reduction be transferred to a distributable reserve account of the Company which may be utilised by the
Company as the board of directors of the Company may deem fit and as permitted under the Act, the amended and restated memorandum of
association adopted by special resolution passed on 1 March 2025 and unanimous written director resolutions passed on 20 February 2025
and made effective on 17 March 2025 (the "Existing Memorandum"), the second amended and restated articles of association
of the Company adopted by special resolution passed on 23 September 2022 (the "Existing Articles"), and all relevant applicable
laws, including, without limitation, eliminating or setting off any accumulated losses of the Company (if any) from time to time;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c) immediately
following the Capital Reduction, pursuant to section 13 of the Act and article 8.1(d) of the Existing Articles, each of the authorised
but unissued Ordinary Shares of par value US$11.25 each be sub-divided into 1,125,000 ordinary shares of par value US$0.00001 each (the
"Sub-division");

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d) immediately
following the Capital Reduction and the Sub-division, the authorised share capital of the Company be altered by the cancellation of:
(i) the 1,250,000 unissued Preferred Shares of par value US$11.25 each; and (ii) 12,020,495,313,338 of the unissued ordinary shares of
par value US$0.00001 each, such that the authorised share capital is altered:

 ****

***from*** US$134,287,453.13338 divided into: (i) 12,022,495,313,338 ordinary shares of par value US$0.00001 each; and (ii) 1,250,000 Preferred Shares of par value US$11.25 each;

 ****

***to*** US$20,000 divided into 2,000,000,000 ordinary shares of par value US$0.00001 each

(the "Capital Alteration");

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;e) immediately
following the Capital Alteration:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. the
authorised and issued share capital of the Company be divided into two separate classes as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i. US$18,000
divided into 1,800,000,000 class A ordinary shares of par value US$0.00001 each (the "Class A Ordinary Shares"); and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ii. US$2,000
divided into 200,000,000 class B ordinary shares of par value US$0.00001 each (the "Class B Ordinary Shares" and, together
with the Class A Ordinary Shares, the "New Share Classes"),

it being noted that the terms of, and rights attaching to the New Share Classes will be materially identical to the existing ordinary shares of par value US$0.00001 each in the capital of the Company save that the Class B Ordinary Shares: (i) shall have 100 times the voting rights per share of Class A Ordinary Shares; and (ii) shall be convertible into Class A Ordinary Shares;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. the
issued shares in the Company outstanding following the Capital Alteration be re-designated, as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i. the
559,868 ordinary shares of par value US$0.00001 each held by Cede & Co be re-designated as 559,868 Class A Ordinary Shares;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ii. the
1 ordinary share of par value US$0.00001 held by Christopher Lin be re-designated as 1 Class A Ordinary Share;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;iii. the
1 ordinary share of par value US$0.00001 held by Michael Olson be re-designated as 1 Class A Ordinary Share;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;iv. the
1 ordinary share of par value US$0.00001 held by Daniel J Sleiman be re-designated as 1 Class A Ordinary Share; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;v. the
3,467 ordinary shares of par value US$0.00001 each held by Sununion Holding Group Limited be re-designated as 3,467 Class B Ordinary
Shares,

(steps (a) to (e) (inclusive) above shall be collectively referred to as the "Capital Reorganisation"),

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;f) any
one or more of the directors of the Company be and is/are hereby authorised to do all such acts and things and execute all such documents,
which are in connection with and/or ancillary to the Capital Reorganisation and any of the foregoing steps and of administrative nature,
on behalf of the Company, including under seal where applicable, as they consider necessary, desirable or expedient to give effect to
the foregoing arrangements for the Capital Reorganisation and (where applicable) to aggregate all fractional Class A Ordinary Shares
and/or Class B Ordinary Shares and sell them for the benefit of the Company." ("Proposal Six")

---

| | | | |
|:---|:---|:---|:---|
| **Resolution** | **For** | **Against** | **Abstain** |
| Proposal Six | 10720 | 3557 | 74 |
| Percentage of Voted Shares: | 75.09% | 24.91% |  |

---

&nbsp;&nbsp;&nbsp;&nbsp;7. "It is resolved, as a special resolution, that subject to and immediately following the Capital Reorganisation being effected,
the Company adopt the amended and restated memorandum and articles of association in the form annexed to the proxy statement (the "A&R
M&A") in substitution for, and to the entire exclusion of, the Existing Memorandum and the Existing Articles, to, amongst other
matters, reflect the Capital Reorganisation and the creation of, and rights attaching to, the New Share Classes." ("Proposal
Seven")

---

| | | | |
|:---|:---|:---|:---|
| **Resolution** | **For** | **Against** | **Abstain** |
| Proposal Seven | 10549 | 3566 | 236 |
| Percentage of Voted Shares: | 74.74% | 25.26% |  |

---

&nbsp;&nbsp;&nbsp;&nbsp;8. "It is resolved, as an ordinary resolution, to adjourn the Meeting to a later date or dates or sine
die, if necessary, to permit further solicitation and vote of proxies if, at the time of the Meeting, there are not sufficient votes for,
or otherwise in connection with, the approval of the foregoing proposals." ("Proposal Eight")

---

| | | | |
|:---|:---|:---|:---|
| **Resolution** | **For** | **Against** | **Abstain** |
| Proposal Eight | 11140 | 3180 | 32 |
| Percentage of Voted Shares: | 77.79% | 22.21% |  |

---

**SIGNATURES**

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | Universe Pharmaceuticals INC. | Universe Pharmaceuticals INC. |
| Date: September 3, 2025 | By: | /s/ Gang Lai |
|  |  | Gang Lai |
|  |  | Chief Executive Officer |

---